tert-butyl 4-(4-chloro-2-methoxyphenyl)-3,6-dihydropyridine-1(2H)-carboxylate | 607744-56-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: tert-butyl 4-(4-chloro-2-methoxyphenyl)-3,6-dihydropyridine-1(2H)-carboxylate
• 英文别名: 4-(4-Chloro-2-methoxyphenyl)-3,6-dihydro-1(2h)-pyridinecarboxylic acid 1,1-dimethylethyl ester；tert-butyl 4-(4-chloro-2-methoxyphenyl)-3,6-dihydro-2H-pyridine-1-carboxylate
• CAS: 607744-56-9
• 化学式: C₁₇H₂₂ClNO₃
• 分子量: 323.82
• InChiKey: WKFXMLSYYFOYJC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(4-chloro-2-methoxyphenyl)-3,6-dihydropyridine-1(2H)-carboxylate 在 platinum(IV) oxide 氢气 、 溶剂黄146 作用下， 以 乙醇 为溶剂， 反应 2.0h， 生成 tert-butyl 4-(4-chloro-2-methoxyphenyl)piperidine-1-carboxylate
  参考文献：
  名称：

  Substituted aryl or heteroarylpiperidine derivatives as melanocortin-4 receptor modulators

  摘要：

  本发明涉及结构式(I)的取代芳基或杂芳基哌啶衍生物，作为黑色素皮质素-4受体调节剂。根据结构和立体化学，本发明的化合物可以是人类黑色素皮质素-4受体(MC-4R)的选择性激动剂或选择性拮抗剂。激动剂可用于治疗肥胖、糖尿病和性功能障碍等疾病，而拮抗剂可用于治疗癌症恶病质、肌肉消耗、厌食症、焦虑和抑郁等疾病。一般来说，所有涉及MC-4R调节的疾病和疾病都可以用本发明的化合物进行治疗。

  公开号：

  EP2020405A1
• 作为产物：
  描述：

  4-chloro-2-methoxyphenyl trifluoroacetate 、 tert-butyl 4-trimethylstannyl-3,6-dihydro-2H-pyridine-1-carboxylate 在 四(三苯基膦)钯 lithium chloride 、 potassium fluoride 作用下， 以 1,4-二氧六环 、 水 、 乙酸乙酯 为溶剂， 反应 1.0h， 以70%的产率得到tert-butyl 4-(4-chloro-2-methoxyphenyl)-3,6-dihydropyridine-1(2H)-carboxylate
  参考文献：
  名称：

  N-sulfonylurea apoptosis promoters

  摘要：

  具有以下化学式的化合物是凋亡促进剂。还公开了制备这些化合物的方法、含有这些化合物的组合物，以及使用这些化合物进行治疗的方法。

  公开号：

  US20030236247A1

文献信息

• Phenylpiperidine derivatives as melanocortin-4 receptor modulators
  申请人：Santhera Pharmaceuticals (Schweiz) AG

  公开号：EP1842846A1

  公开（公告）日：2007-10-10

  The present invention relates to substituted phenylpiperidine derivatives as melanocortin-4 receptor modulators. Depending on the structure and the stereochemistry the compounds of the invention are either selective agonists or selective antagonists of the human melanocortin-4 receptor (MC-4R). The agonists can be used for the treatment of disorders and diseases such as obesity, diabetes and sexual dysfunction, whereas the antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, anxiety and depression. Generally all diseases and disorders where the regulation of the MC-4R is involved can be treated with the compounds of the invention.

  本发明涉及取代苯基哌啶衍生物作为黑色素皮质素-4受体调节剂。根据结构和立体化学，本发明的化合物要么是人类黑色素皮质素-4受体（MC-4R）的选择性激动剂，要么是选择性拮抗剂。激动剂可用于治疗肥胖、糖尿病和性功能障碍等疾病，而拮抗剂可用于治疗癌症恶病质、肌肉消耗、厌食症、焦虑和抑郁等疾病。一般来说，涉及MC-4R调节的所有疾病和疾病都可以用本发明的化合物进行治疗。
• Substituted phenylpiperidine derivatives as melanocortin-4 receptor modulators
  申请人：Santhera Pharmaceuticals (Schweiz) AG

  公开号：EP1826201A1

  公开（公告）日：2007-08-29

  The present invention relates to substituted phenylpiperidine derivatives as melanocortin-4 receptor modulators. Depending on the structure and the stereochemistry the compounds of the invention are either selective agonists or selective antagonists of the human melanocortin-4 receptor (MC-4R). The agonists can be used for the treatment of disorders and diseases such as obesity, diabetes and sexual dysfunction, whereas the antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, anxiety and depression. Generally, all diseases and disorders where the regulation of the MC-4R is involved can be treated with the compounds of the invention.

  本发明涉及替代苯基哌啶衍生物作为黑色素皮质激素-4受体调节剂。根据结构和立体化学，本发明的化合物可以是人类黑色素皮质激素-4受体（MC-4R）的选择性激动剂或选择性拮抗剂。激动剂可用于治疗肥胖、糖尿病和性功能障碍等疾病，而拮抗剂可用于治疗癌症消耗症、肌肉消耗、厌食症、焦虑和抑郁等疾病。一般来说，所有涉及MC-4R调节的疾病和障碍都可以用本发明的化合物来治疗。
• N-SULFONYLUREA APOPTOSIS PROMOTERS
  申请人：Elmore Steven W.

  公开号：US20080146572A1

  公开（公告）日：2008-06-19

  Compounds having the formula are apoptosis promoters. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

  具有以下化学式的化合物是凋亡促进剂。还公开了制备这些化合物的方法，含有这些化合物的组合物以及使用这些化合物进行治疗的方法。
• SUBSTITUTED PHENYLPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS
  申请人：Santhera Pharmaceuticals (Schweiz) AG

  公开号：EP2004604B1

  公开（公告）日：2010-12-01
• Substituted Phenylpiperidine Derivatives As Melanocortin-4 Receptor Modulators
  申请人：Soeberdt Michael

  公开号：US20110086836A1

  公开（公告）日：2011-04-14

  The present invention relates to substituted phenylpiperidine derivatives as melanocortin-4 receptor modulators. Depending on the structure and the stereochemistry the compounds of the invention are either selective agonists or selective antagonists of the human melanocortin-4 receptor (MC-4R). The agonists can be used for the treatment of disorders and diseases such as obesity, diabetes and sexual dysfunction, whereas the antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, anxiety and depression. Generally all diseases and disorders where the regulation of the MC-4R is involved can be treated with the compounds of the invention.